Olanzapine Market Research Report, by Application (Schizophrenia, Bipolar disorder, other) by types (ZYPREXA tablets, ZYPREXA ZYDIS and ZYPREXA IntraMuscular), by region (Europe, Americas, Asia Pacific and Middle East & Africa) - Global Forecast to 2027

Market Insights

Olanzapine which was initially branded as Zyprexa is a generic drug that has been adopted globally as an essential treatment drug for schizophrenia and bipolar disorder among others. Market Research Future has published its report on the global olanzapine market which estimates a substantial CAGR during the forecast period of 2017 to 2027.

Get Free Sample @ https://www.marketresearchfuture.com/sample_request/718

Increasing global population and increased awareness of neurological and mental disorders have led to an increase in diagnoses which has created a demand for effective treatment options, thus facilitating market growth. Globally, the social stigma associated with mental illnesses and neurological disorder has reduced which has prompted consumers to seek treatment.

Changing lifestyles, rapidly evolving technology and pace of life has given rise to an increased occurrence of various disorders which in turn has motivated the growth of the olanzapine market.

Side effects associated with olanzapine and the development of more effective drugs is likely to restrain market growth. However, due to the history of the effectiveness of this drug, its participation in the development of effective drug combinations and the high demand for olanzapine in emerging economies is expected to encourage robust growth for this market.

Market Segmentation

MRFR's segmental analysis of the olanzapine market insight provides an expansive view of the market components which help identify trends and opportunities. The global olanzapine market has been segmented by application, types, and region.

By application, the market has been segregated to include schizophrenia, bipolar disorder, and others.

By types, the market has been divided into Zyprexa tablets, Zyprexa zydis and Zyprexa intramuscular.

By region, the global market has been divided into the Americas, Europe, Asia Pacific and the Middle East & Africa.

Regional Analysis

The Asia-Pacific presently controls the most significant market share with an approximate CAGR of over 26% during the forecast period with China leading at a 27% CAGR. The region is one of the most densely populated areas worldwide, with a strong presence of various developing economies where there are rising diagnoses of mental illnesses such as schizophrenia and bipolar disorder and a definite requirement for essential treatment drugs.

Europe has the second-most significant share of the market, and olanzapine was first released in this region. This has been a primary reason for Europe's position in the global market for olanzapine.

Americas’ have the third largest share, with North America being the largest contributor to growth due to the developed healthcare in the region and demand for this essential drug.

Key Players

Prominent players that contribute substantially to the competitive landscape of the global olanzapine market include Sandoz, Watson Pharmaceuticals (ChangZhou), Hanson Pharmaceuticals, Hansoh Pharmaceuticals, Zhejiang Langhua Pharmaceuticals, Eli Lilly, Dr Reddy's Pharmaceuticals, Mylan Pharmaceuticals, Sun Pharmaceuticals, Apotex Inc., Teva Pharmaceuticals, Torrent Pharmaceuticals, Jubilant Lifesciences and Aurobindo Pharma.

Analysis of the competitive landscape offers an expansive view of the market and assists in the identification of opportunities and existing trends.



Latest Industry News

Findings of a recent trial of the investigational drug, ALKS 3831 which is a combination of olanzapine-samidorphan, revealed that the combination did not outperform olanzapine alone. However, it was found to improve overall symptoms of schizophrenia. The experimental drug received a lot of press for its novel once-a-day and atypical formulation. The study was conducted over four weeks, was randomized, double-blind and placebo-controlled. The treatment option may find potential in treating acute schizophrenia.



Published findings of a 52-week clinical trial have disclosed that a reduction in dosage of antipsychotics such as olanzapine and risperidone during the maintenance stage of treatment can improve cognitive function and decrease overall negative symptoms without increasing the chances of relapse.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: [email protected]